Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials

…, PS Yamauchi, M Zirwas, L Albrecht, AR Devani… - Jama, 2022 - jamanetwork.com
Importance Once-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor,
demonstrated efficacy and was well tolerated in a phase 2b trial of patients with psoriasis. …

Recent advancements and developments in search of anti-tuberculosis agents: a quinquennial update and future directions

…, KA Bhakhar, ND Gajjar, KA Patel, AA Devani… - Journal of Molecular …, 2022 - Elsevier
Tuberculosis (TB) has been considered as the highly chronic, contagious and infectious
disorder caused by Mycobacterium tuberculosis (Mtb). Every year more than 10 million patients …

Comprehensive Coverage on Anti‐mycobacterial Endeavour Reported in 2021

TM Dhameliya, AA Devani, KA Patel… - ChemistrySelect, 2022 - Wiley Online Library
Tuberculosis (TB) has been the highly contagious airborne disease caused by Mycobacterium
tuberculosis and the major leading infectious disease with the higher upsurge of …

The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis.

AS Russell, AL Devani, WP Maksymowych - The Journal of …, 2006 - jrheum.org
OBJECTIVE: To determine whether the presence of anti-cyclic citrullinated peptide (anti-CCP)
antibodies at presentation is of prognostic value in patients with palindromic arthritis. …

Management of pediatric generalized pustular psoriasis using biologics: an evidence-based review

…, NJ Luca, P Miettunen, R Stevenson, AR Devani… - Journal of the American …, 2022 - jaad.org
… Dr Devani has been an advisor, consultant, speaker, and/or investigator for AbbVie,
Amgen, Arcutis, Arena, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, …

Incidence of COVID-19 in patients with chronic idiopathic urticaria and asthma on omalizumab: a multicentre retrospective cohort study

…, A Mufti, AR Devani… - Journal of …, 2022 - journals.sagepub.com
Omalizumab is a humanized recombinant immunoglobulin (Ig) G1 monoclonal antibody that
targets free IgE, resulting in reduced inflammatory mediator release from mast cells and …

Implementation of E-health care system using web services and cloud computing

U Dhanaliya, A Devani - 2016 International Conference on …, 2016 - ieeexplore.ieee.org
For economical, technological and social development of any country needs enhanced
health care system. Development of health care system necessitates large no of manpower, …

Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study

…, N Bhatia, M Bukhalo, AR Devani… - British Journal of …, 2023 - academic.oup.com
Background Scalp psoriasis affects most patients with psoriasis, but it can be difficult to treat.
Objectives To evaluate the efficacy and safety of once-daily roflumilast foam 0.3% on scalp …

Incidence and prognosis of COVID‐19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study

…, A Mufti, AR Devani… - Journal of the …, 2022 - Wiley Online Library
Exacerbated systemic signs/symptoms, including respiratory distress, with SARS-CoV-2
infection (COVID-19) have been linked to a disruption in the balance of pro-and anti-…

Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study

…, M Sachdeva, A Mufti, AR Devani… - Journal of …, 2022 - Taylor & Francis
Despite recent advances, the effects of immune-modulating biologic therapies on the clinical
course of COVID-19 remains unclear (1). There are heightened concerns of an increased …